Get the Stockscreener App
4.345
9.10%
-0.435
After Hours:
4.26
-0.085
-1.96%
Relay Therapeutics Inc stock is traded at $4.345, with a volume of 1.97M.
It is down -9.10% in the last 24 hours and down -7.75% over the past month.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
See More
Previous Close:
$4.78
Open:
$4.77
24h Volume:
1.97M
Relative Volume:
0.93
Market Cap:
$727.28M
Revenue:
$25.55M
Net Income/Loss:
$-341.97M
P/E Ratio:
-1.5518
EPS:
-2.8
Net Cash Flow:
$-304.44M
1W Performance:
-5.95%
1M Performance:
-7.75%
6M Performance:
-47.27%
1Y Performance:
-60.50%
1-Day Range:
$4.24
$4.85
1-Week Range:
$4.00
$5.99
52-Week Range:
$4.00
$11.16
Relay Therapeutics Inc Stock (RLAY) Company Profile
Name
Relay Therapeutics Inc
Sector
Industry
Phone
617-370-8837
Address
399 BINNEY STREET, CAMBRIDGE
Compare RLAY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
4.345 | 727.28M | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
411.66 | 106.01B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
690.87 | 75.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.60 | 39.80B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.51 | 31.02B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
112.43 | 26.95B | 3.30B | -501.07M | 1.03B | -2.1146 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-10-24 | Resumed | Goldman | Buy |
| Sep-10-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-10-24 | Downgrade | Oppenheimer | Outperform → Perform |
| May-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-20-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-19-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-23 | Initiated | Raymond James | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Sep-30-22 | Initiated | Barclays | Equal Weight |
| Sep-02-22 | Initiated | Stifel | Buy |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Jul-21-21 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-08-20 | Initiated | JMP Securities | Mkt Outperform |
| Nov-05-20 | Initiated | H.C. Wainwright | Buy |
| Aug-10-20 | Initiated | Cowen | Outperform |
| Aug-10-20 | Initiated | Goldman | Buy |
| Aug-10-20 | Initiated | Guggenheim | Buy |
| Aug-10-20 | Initiated | JP Morgan | Neutral |
View All
Relay Therapeutics Inc Stock (RLAY) Latest News
Relay Therapeutics (NASDAQ:RLAY) Shares Down 4.8%Here's Why - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Given "Buy" Rating at HC Wainwright - MarketBeat
Relay Therapeutics Highlights Progress at Healthcare Conference - TipRanks
Barclays PLC Grows Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Barclays PLC Purchases 136,541 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Relay Therapeutics stock hits 52-week low at $4 By Investing.com - Investing.com South Africa
Relay Therapeutics (NASDAQ:RLAY) Hits New 12-Month LowShould You Sell? - MarketBeat
Relay Therapeutics stock hits 52-week low at $4 - Investing.com India
Eli Lilly in talks to acquire Scorpion Therapeutics, FT says; Relay Therapeutics seesaws - MSN
Eli Lilly in talks to acquire Scorpion Therapeutics, FT says; Relay Therapeutics seesaws (LLY:NYSE) - Seeking Alpha
Relay Therapeutics Chief Corporate Development Officer Peter Rahmer Sells 63% Of Holding - Simply Wall St
Relay Therapeutics (NASDAQ:RLAY) Stock Price Up 4.8%Should You Buy? - MarketBeat
Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Relay Therapeutics officer sells shares worth $345,571 By Investing.com - Investing.com Australia
Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Sells $73,763.20 in Stock - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Peter Rahmer Sells 32,156 Shares - MarketBeat
Relay Therapeutics officer sells shares worth $345,571 - Investing.com
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Bought by JPMorgan Chase & Co. - Defense World
JPMorgan Chase & Co. Grows Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Layoff Tracker: Regeneron Acquisition of Oxular Wipes Out Oxular Workforce - BioSpace
Relay Therapeutics stock hits 52-week low at $4.11 amid market challenges - Investing.com Australia
Relay Therapeutics president sells shares for $2,877 By Investing.com - Investing.com Australia
Relay Therapeutics’ chief corporate development officer sells $1,752 in stock By Investing.com - Investing.com Nigeria
Relay Therapeutics' chief corporate development officer sells $1,752 in stock By Investing.com - Investing.com Australia
Relay Therapeutics president sells shares for $2,877 - Investing.com India
Relay Therapeutics' chief corporate development officer sells $1,752 in stock - Investing.com India
Relay Therapeutics chief legal officer sells $1,309 in stock By Investing.com - Investing.com Nigeria
Relay Therapeutics chief legal officer sells $1,309 in stock - Investing.com India
Thomas Catinazzo Sells 4,865 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock - MarketBeat
Relay Therapeutics CFO sells $21,490 in stock By Investing.com - Investing.com Nigeria
Relay Therapeutics CFO sells $21,490 in stock - Investing.com
Relay Therapeutics stock hits 52-week low at $4.11 amid market challenges By Investing.com - Investing.com South Africa
Relay Therapeutics (NASDAQ:RLAY) Sets New 52-Week LowTime to Sell? - MarketBeat
Is Relay Therapeutics (RLAY) the Best Biotech Penny Stock to Invest in Now? - Insider Monkey
12 Best Biotech Penny Stocks To Invest In Now - Insider Monkey
Jane Street Group LLC Trims Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock Holdings Increased by Geode Capital Management LLC - Defense World
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Purchased by Geode Capital Management LLC - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Bought by Barclays PLC - MarketBeat
Barclays PLC Acquires 136,541 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics (NASDAQ:RLAY) & Tectonic Therapeutic (NASDAQ:TECX) Critical Contrast - Defense World
Relay Therapeutics Inc Stock (RLAY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.13%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):